✦ LIBER ✦

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

✍ Scribed by Bertrand Coiffier; Evgenii A Osmanov; Xiaonan Hong; Adriana Scheliga; Jiri Mayer; Fritz Offner; Simon Rule; Adriana Teixeira; Jan Walewski; Sven de Vos; Michael Crump; Ofer Shpilberg; Dixie-Lee Esseltine; Eugene Zhu; Christopher Enny; Panteli Theocharous; Helgi van de Velde; Yusri A Elsayed; Pier Luigi Zinzani

Book ID: 117785696
Publisher: The Lancet
Year: 2011
Tongue: English
Weight: 350 KB
Volume: 12
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(11)70150-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bortezomib plus rituximab versus rituxim

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

✍ Pier Luigi Zinzani, Nuriet K Khuageva, Huaqing Wang, Bernardo Garicochea, Jan Wa 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 253 KB

Phase 2 trial of rituximab and bortezomi

Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma

✍ Robert A. Baiocchi; Lapo Alinari; Mark E. Lustberg; Thomas S. Lin; Pierluigi Por 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 257 KB 👁 1 views

Rituximab maintenance for 2 years in pat

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

✍ Gilles Salles; John Francis Seymour; Fritz Offner; Armando López-Guillermo; Davi 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 320 KB

Bendamustine plus rituximab versus CHOP

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

✍ Rummel, Mathias J; Niederle, Norbert; Maschmeyer, Georg; Banat, G Andre; von Grü 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 312 KB

Oral lenalidomide with rituximab in rela

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

✍ Wang, M; Fowler, N; Wagner-Bartak, N; Feng, L; Romaguera, J; Neelapu, S S; Hagem 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 817 KB

Oral lenalidomide with rituximab in rela

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

✍ Wang, M; Fowler, N; Wagner-Bartak, N; Feng, L; Romaguera, J; Neelapu, S S; Hagem 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 817 KB

Lenalidomide-rituximab therapy is effective in grade 1-2 follicular and mantle cell lymphoma, but its efficacy in diffuse large B-cell lymphoma (DLBCL), transformed large cell lymphoma (TL) and grade 3 follicular lymphoma (FLG3) is unknown. In this phase II trial, 45 patients with relapsed or refrac